Hereditary Cancer Screening

Ask our staff how you can qualify for a No Cost Screening.

Cancer screening and genomics testing analyzes mutations in a patient’s DNA known to be associated with an increased risk of hereditary cancer. Our laboratory provides a comprehensive report indicating a patient’s potential susceptibility to various hereditary cancers. This testing uses the latest next generation sequencing technology to analyze patient samples in a rapid and accurate fashion. This information helps guide a clinician’s route of personalized therapy dependent on the specific genomic mutation and associated cancer.

Screens for the following Types of Cancer

• Breast Cancer
• Ovarian Cancer
• Gastric Cancer
• Skin Cancer
• Uterine/Endometrial Cancer
• Testicular Cancer
• Pancreas Cancer
• Colorectal Cancer
• Prostate Cancer

Type of Test Procedure:

Easy 1,2,3 Performed by our Medically Trained Staff with a Mouth Swab Kit. Quick Effortless and Painless.

Pharmacogenetics (PGx) Screening

We offer pharmacogenetic testing to help maximize the effectiveness and minimize the side effects of prescribed medications. Knowing how a patient will metabolize certain medications based on their personal gene variants can help determine the selection and dosage of some of the most commonly prescribed drugs. Equipped with this information, healthcare providers can feel confident that they are offering the best informed diagnosis and treatment plan.

Why PGx Testing?

• Individualize patient medication therapies
• Optimize the safety and efficacy of prescription regimens
• Maximize safety by reducing “trial-and-error” prescribing
• Save patients time and money

The Importance of Testing

By providing clear, actionable guidance, our Laboratories lets clinicians address the complexities of drug interactions and the impact of individual genetics on drug metabolization. This leads to better prescribing decisions, reduced ADEs, improved patient outcomes, and lower healthcare costs.

Currently, the labels of more than 100 U.S. Food and Drug Administration-approved medications include information about the impact of genetic variations on drug efficacy (See Testing Reference). For health care providers to make optimal prescribing decisions for these medications, it is important to have information on each patient’s unique genetic background.

There are several common, well-documented genetic variations that substantially reduce or increase the functionality of enzymes involved in metabolizing frequently prescribed drugs. If a patient’s DNA contains one or more of these variants, it may significantly affect their ability to break down and absorb many commonly prescribed medications, resulting in reduced efficacy of the medication, or increased risk of adverse drug reactions.¹

FDA Table of Pharmacogenomic Biomarkers in Drug Labeling

Our Genetic Tests

Pain Management Panel

Identifies genetic variants that affect how an individual will respond to the analgesic effects of certain types of commonly prescribed pain medications. Genes Tested: CYP1A2, CYP2D6, CYP2C19, CYP3A4, CYP3A5, CYP2B6, CYP2C9, OPRM1, Factor ll, Factor V, MTHFR

Cardiovascular Panel

Tests for the genetic risk of a variety of heart-related health conditions. Genes Tested: CYP2C19, CYP2D6, CYP2C9, VKORC1, CYP3A4, CYP3A5, Factor ll, Factor V, MTHFR , APOE, SLCO1B1

Mental Health Panel

Identifies genetic variants that affect the metabolism and efficacy of psychiatric medications. Genes Tested: CYP1A2, CYP2D6, CYP2C19, CYP2C9, CYP3A, CYP3A4, CYP3A5, COMT, ANKK1/DRD2

Orthopedic Panel

Identifies genetic variants that identify inherited coagulation pathway deficits that increase thrombosis risk and affect how an individual will respond to the analgesic effects of certain types of commonly prescribed pain medications.  Genes Tested: CYP2D6, CYP2C19, VKORC1, CYP3A4, CYP3A5, OPRM1, Factor ll, Factor V, MTHFR

Molecular Diagnostic Solutions for Chronic Infections

Disorders caused by pathogens like bacteria, virus, fungi, etc. are called infectious disease. Worldwide millions of deaths are caused by microbial infections. Early detection of pathogens is important to determine effective treatment and long-term management of infected patients. Molecular testing of infectious pathogens is mandatory to opt for treatment and monitor the therapy. Our Laboratories are committed to use highly sensitive molecular technology for qualitative and quantitative measurement of pathogen, to help clinician monitor status of the disease and detect drug resistance.

Bacteria grow as either individual (planktonic) cells or in complex communities of cells called biofilms. Infections caused by biofilms, often harboring many different types of micro-organisms, have been shown to be much more resistant to treatment. It is now believed that over 99 percent of all bacteria live as a community and attach to surfaces as biofilms. According to the National Institutes of Health, it is believed that approximately 80 percent of all infections in humans are related to biofilms. With next-generation sequencing technology offered by our laboratories, physicians are able to know exactly which pathogenic micro-organisms are present in any biofilm. Biofilms have been shown to play a role in many infections of the ear, nose, throat, and respiratory tract, including: ear (recurrent acute otitis media, otitis media with effusion, cholesteatoma), chronic tonsillitis, chronic pharyngitis, chronic rhinosinusitis, sinusitis, epiglottitis, laryngotracheitis, pneumonia, and infections of tracheostomies, endotracheal tubes, tympanostomy tubes, pulmonary infections in cystic fibrosis, chronic bronchitis and bronchiolitis.

CONTACT US: